Lassa Pseudovirus

Comprehensive Neutralization Assay Solutions for Advancing Lassa Research

Get your pseudovirus

Lassa pseudovirus Advantages

We produce a pseudovirus pseudotyped with the Lassa virus, Mouse/Sierra Leone/Josiah/1976 variant. These pseudoviruses carry a modified genome that expresses a luciferase or a GFP reporter gene.

Up to 1,000 reactions per mL (96-well plate)

Get a signal-to-background ratio of ≥10³ with 1 µL per well in a 96-well plate

Infectious titer of at least 10⁵ RLU/µL

The transduction efficiency is evaluated using HEK293T cells.

Lot to lot functionally validated

Infectivity and neutralization are evaluated for each batch

Lead Time: 2 - 3 week

We provide you with freshly produced pseudoviruses

QC report Order Now

Features

Enable specific detection

Expression of the Lassa Glycoprotein as the sole surface antigen (Uniprot Accession Number: P08669)

Enhanced safety

Our pseudoviruses use a 3rd-generation lentivirus core and must be handled in BSL-2 conditions

Characterization of thermal stability

Stable at least 6 month at -80 °C

Support high-throughput screening

QR report Order Now

Applications

Pseudoviruses provide a safe and versatile platform for Lassa virus research and the development of therapeutic countermeasures. Lassa pseudoviruses have several important applications in research and development, including:

Vaccine Development

They are used to test the efficacy of new vaccines by evaluating their ability to induce neutralizing immune responses without the need for live pathogenic viruses.

Neutralizing Monoclonal Antibody Screening

Pseudoviruses enable rapid and safe screening of monoclonal antibodies targeting specific strains of the Lassa virus.

Antiviral Resistance Studies

They help study viral mutations and evaluate how these mutations affect sensitivity to antiviral treatments.

Fundamental Research on Viral Entry

Pseudoviruses are used to understand the mechanisms of viral entry into host cells, which is crucial for developing new therapies targeting these processes.

Treatment Efficacy Testing

They allow for the quick assessment of new antiviral agents’ effectiveness in controlled environments without the risks associated with highly pathogenic viruses.

Order Now

Background

The Lassa virus (strain Mouse/Sierra Leone/Josiah/1976) is a well-characterized, historically significant isolate of Lassa mammarenavirus, an Old World arenavirus responsible for causing Lassa fever, a severe viral hemorrhagic disease endemic to West Africa. This strain, commonly referred to as the Josiah strain, was originally isolated from a human case in Sierra Leone in 1976 and has been extensively sequenced and used as a reference strain in molecular and structural studies due to its representative genomic features and clinical relevance. The virus possesses a bi-segmented, negative-sense RNA genome, with the small (S) segment encoding the nucleoprotein and glycoprotein precursor and the large (L) segment encoding the polymerase (L) and zinc-binding (Z) proteins; these features are typical of arenaviruses and are essential for viral replication and pathogenesis. Because Lassa virus is maintained in nature by rodent reservoirs such as Mastomys natalensis and can cause severe human disease with significant mortality, the Josiah strain has been broadly used to support vaccine research, diagnostic assay development, and structural biology aimed at understanding viral entry and immune recognition.

Lassa pseudovirus in Publications

The ongoing burden of Lassa fever in West Africa, driven by Lassa virus strains such as Mouse/Sierra Leone/Josiah/1976, underscores the urgent need for effective vaccines and antiviral strategies. By eliminating the need to handle highly pathogenic BSL-4 infectious virus, pseudovirus neutralization assays offer a safe, rapid, scalable, and standardized platform for evaluating neutralizing monoclonal antibodies (mAbs) and antiviral compounds targeting the glycoprotein (GP) of Lassa virus.

• A validated and standardized pseudotyped microneutralization assay as a safe and powerful tool to measure LASSA virus neutralising antibodies for vaccine development and comparison

Documentations

Quality Control Report

Access all QR reports

SDS

Access SDS

×

Get your document

Fill out the form below to get your document

"*" indicates required fields

Name*

First Last

Email*

This field is hidden when viewing the form

Document URL